Skip to main content

Mavorixafor

Pronunciation: MAV-or-ix-a-for
Generic name: mavorixafor
Brand name: Xolremdi
Dosage form: oral capsule (100 mg)
Drug class: Other immunostimulants

Medically reviewed by Carmen Pope, BPharm. Last updated on May 12, 2025.

What is Mavorixafor?

Mavorixafor is used to treat WHIM syndrome (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis syndrome) in adults and children 12 years of age and older. It is an oral capsule that is taken once a day.

Mavorixafor gained FDA approval on 26 April 2024 under the brand name Xolremdi. There is no generic.

Mechanism. How does mavorixafor work?

Mavorixafor works by targeting the CXCR4 receptor, preventing the binding of another substance, called stromal-derived factor-1α (SDF-1α)/CXC Chemokine Ligand 12 (CXCL12). The SDF-1/CXCR4 system is crucial for the movement of leukocytes (a type of white blood cell) to and from the bone marrow. Mavorixafor blocks the response to wild-type and mutated CXCR4 variants associated with WHIM syndrome, increasing levels of circulating mature neutrophils and lymphocytes.

Mavorixafor belongs to the drug class called oral CXCR4 antagonists.

Side effects

The most common side effects of mavorixafor are:

Serious side effects and warnings

Mavorixafor may cause the following serious side effects:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to X4 Pharmaceuticals, Inc. at 1-866-MED-X4MI (1-866-633-9464) or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before taking

Do not take mavorixafor if you have severe or end-stage kidney disease, or moderate to severe liver disease.

Before taking mavorixafor, tell your healthcare provider about all your medical conditions, including if you:

Pregnancy

You may need to have a negative pregnancy test before starting mavorixafor. Do not take this medication if you are pregnant.

Mavorixafor may harm an unborn baby and affect the development of its placenta. Females with childbearing potential should use effective contraception while receiving mavorixafor and for 3 weeks after the last dose. If you become pregnant while receiving mavorixafor, tell your doctor right away.

Breastfeeding

You should not breastfeed while taking mavorixafor and for 3 weeks after the last dose. Talk to your healthcare provider about the best way to feed your baby.

How do I take mavorixafor?

Mavorixafor is a capsule that is taken 1 time a day before breakfast.

Dosing information

Mavorixafor dosage for WHIM syndrome: 

What should I avoid while taking mavorixafor?

Advise eating or drinking products that contain grapefruit, because grapefruit is a strong CYP3A4 inhibitor and may increase the risk of side effects from mavorixafor.

What other drugs will affect mavorixafor?

Other drugs may interact with mavorixafor, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using. Especially tell your doctor if you take:

This is not a complete list of interactions. Talk to your healthcare provider or pharmacist about drug interactions. 

Does mavorixafor interact with my other drugs?

Enter medications to view a detailed interaction report using our Drug Interaction Checker.

Storage

Store mavorixafor capsules in the refrigerator at 2°C to 8°C (36°F to 46°F). Keep it in the original container to protect it from moisture and tightly closed.

Ingredients

Xolremdi ingredients

Active: mavorixafor 100mg.

Inactive: colloidal silicon dioxide, croscarmellose sodium, dibasic calcium phosphate dihydrate, microcrystalline cellulose, sodium lauryl sulfate, and sodium stearyl fumarate.

Hard gelatin capsule: FD&C Blue #2, gelatin, and titanium dioxide.

Black Ink: ammonium hydroxide 28%, ferrosoferric oxide/black iron oxide (E172), isopropyl alcohol, n-butyl alcohol, propylene glycol, and shellac glaze in ethanol.

Available as 100 mg capsules.

Manufacturer

Mavorixafor is manufactured by X4 Pharmaceuticals, Inc., under the brand name Xolremdi. X4 Pharmaceuticals Inc. is based in Boston, Massachusetts, USA, and its focus is on rare diseases and other limited treatment opportunities.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.